Navigation Links
Ohr Pharmaceutical Announces $5 Million Financing from Exercise of Warrants
Date:4/22/2013

NEW YORK, April 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced that Ohr raised approximately $5.05 million dollars from institutional and accredited shareholders through the exercise of Series B Warrants.  The Company intends to use the net proceeds from this offering to complete its Phase II Squalamine eye drop clinical trial for the wet form of age-related macular degeneration, further the clinical development of Squalamine eye drops for the treatment of other neovascular ophthalmic disorders, fund continued development of other pipeline molecules, and for general corporate purposes.

"The Company's ability to raise significant capital on favorable terms and provide itself with a cash runway into 2015 is a confirmation of the continued progress on the Company's clinical development programs," said Ira Greenstein , Chairman of the Board of Directors. "The additional capital will allow us to continue to execute on the Company's strategy and increases shareholder equity, one of the requirements for our proposed uplisting to Nasdaq."

"We would like to thank our shareholders for their continued support," said Dr. Irach B. Taraporewala, CEO of Ohr Pharmaceutical. "I am pleased to report that we anticipate completing 50% enrollment in the Phase II Squalamine eye drop trial midyear and look forward to continuing to update shareholders on the progress of our clinical trial and business initiatives."   

About the Warrant Exercise

On April 5, 2013, the Company gave notice to Series B Warrant holders that the Company was opting to accelerate the expiration date of the Series B Warrants to April 18, 2013. Additionally, as an incentive to encourage exercise of the Series B Warrants, the Company offered to those Series B Warrant holders
'/>"/>

SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
2. Shimadzu's New DSC-60 Plus Series Differential Scanning Calorimeters Offer High-Sensitivity Analysis in Polymer, Food and Pharmaceutical Applications
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
5. North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017
6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
8. Executives from Johnson & Johnson, GlaxoSmithKline and California State Board of Pharmacy discuss pharmaceutical packaging challenges at Pharmapack North America 2013
9. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
10. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... has launched PATHT HTS, a new platform for high-throughput ... the microarray industry's annual conference, Chips To Hits in ... the performance of PATH protein microarray slides," said Robert ... BioSurfaces. "PATH HTS was designed to meet the ...
... The NeuronFarm, a developer of Web-based applications intended ... immediate availability of its flagship product, 3D-Readers. , ... third through eighth graders in several school studies, ... automated text scoring, engaging simulations and immediate feedback ...
... As more organizations look at what needs to be ... an area that has come under the spotlight is ... corporate governance issues have become issues even within the ... Act (SOX) has become a reason to organize and ...
Cached Biology Technology:NeuronFarm's 3D-Reader ready to ship 2Sarbox necessitating ECM software, but beware of `best practices' 2Sarbox necessitating ECM software, but beware of `best practices' 3
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... at the University of Kentucky has discovered new methods ... , The research, led by Peixuan Guo, professor ... the UK College of Pharmacy and Markey Cancer Center, ... Boiling-Resistant Anionic Polymer Material To Build Robust Structures with ... and Daniel L. Jasinski. , The article, which will ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... has discovered the first identified droplets of spider blood in ... , Two droplets of blood, technically known as haemolymph, have ... - Filistatidae - a family commonly found in South America ... examples of spider blood ever found in an amber fossil. ...
... painkiller prompts brain to release endorphins, bringing real relief ... medicine will relieve pain is enough to prompt the ... painful sensations, a new University of Michigan study finds. ... the brain's own pain-fighting chemicals, called endorphins, play a ...
... completed 60 days of voluntary bedrest in order to ... body. The research team in Toulouse, France, is now ... continue and enhance the research. , At the beginning ... of the WISE study (Women International Simulation Experiment), were ...
Cached Biology News:Spider blood found in 20 million year old fossil 2Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 2Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 3Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 4Female volunteers prepare for a second 'bedrest' 2
Recombinant Rat Leptin, CF...
delta-like 1 homolog (Drosophila)...
... 71-18 mutS and ES1301 mutS are mismatch ... of these strains prevents repair of the ... high mutation efficiencies and making them helpful ... Altered Sites II Mutagenesis Systems. Both ES1301 ...
Request Info...
Biology Products: